A Phase 3 interventional study of FluBlok® and Placebo in Influenza, sponsored by Sanofi. Completed at 24 sites in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-06.
Sponsored by Sanofi · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing FluBlok in Influenza, Human — none open to participants now, none under way, none of them phase 3. FluBlok · Influenza, Human.
Among the 11 studies testing FluBlok in Influenza, Human, this one has the largest enrollment, is one of 2 that started in 2007, is one of 3 in phase 3, and was the 2nd registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →None of the 11 studies testing FluBlok in Influenza, Human is open now. The open studies under Influenza, Human, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: 18 Years to 49 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 4 · Phase 4 5
First in 2004; this study’s year is marked. 2 started in 2007.
This study's enrollment of 4,648 is above the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 606 across the 11 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 11 have an industry lead sponsor. The 8 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
139 studies in Influenza, Human by Sanofi: 4 open now, 6 under way, 1 of them phase 3. Of 133 finished, 73 (55%) have results posted.
Among the 139 studies in Influenza, Human by Sanofi, this one is the 6th largest by enrollment of the 126 interventional ones that give a count, is one of 13 that started in 2007, is one of 35 in phase 3, and was the 21st registered.
Sanofi’s Influenza, Human studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing FluBlok in Influenza, Human, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 139 in Influenza, Human:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate a single dose of FluBlok in terms of safety, efficacy and effectiveness in prevention of influenza and influenza-like illness and assess clinical lot-to-lot consistency in manufacturing by evaluating and comparing the immunogenicity of three different lots of FluBlok in a subset of participants.
All currently licensed influenza vaccines in the United States were produced in embryonated hen's eggs. There were several well-recognized disadvantages to the use of eggs as the substrate for influenza vaccine. Eggs required specialized manufacturing facilities and could be difficult to scale up rapidly in response to an emerging need such as a pandemic. It was usually necessary to adapt candidate vaccine viruses for high-yield growth in eggs, a process that could be time consuming, was not always successful, and could select receptor variants that might have suboptimal immunogenicity. In addition, agricultural diseases that affected chicken flocks, and that might be an important issue in a pandemic due to an avian influenza virus strain, could easily disrupt the supply of eggs for vaccine manufacturing. Therefore, development of alternative substrates for influenza vaccine production had been identified as a high-priority objective.
One potential alternative method for production of influenza vaccine was expression of the influenza virus hemagglutinin (HA) using recombinant deoxyribonucleic acid (DNA) techniques. This alternative avoided dependence on eggs and was very efficient because of the high levels of protein expression under the control of the baculovirus polyhedrin promoter.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single 0.5 milliliters (mL) dose of FluBlok vaccine from any of the Lots A, B, or C, intramuscularly on Day 0 (Visit 1). Participants were followed up to 6 months after vaccination.
Biological: FluBlok®
Participants received a single dose of placebo matched to FluBlok, intramuscularly on Day 0 (Visit 1). Participants were followed up to 6 months after vaccination.
Biological: Placebo
Dose: 0.5 mL, single dose; Route of administration: intramuscular. Recombinant Trivalent Hemagglutinin Influenza Vaccine containing 45 microgram (mcg) of each hemagglutinin derived from A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
Also known as: rHA Trivalent Recombinant Hemagglutinin Influenza Vaccine
Dose: 0.5 mL normal saline for injection, single dose; Route of administration: intramuscular
Number of Participants Reporting Solicited Injection Site (Local) Reactions
Solicited reaction (reactogenicity event) was an adverse event (AE) that was pre-listed in electronic case report form(eCRF), considered to be related to vaccination and recorded by participant by means of memory aid. Injection sites reaction included pain,bruising,redness,swelling. Pain and bruising:Grade0: didn't have it at all; Grade1: noticed it, but it didn't interfere with usual activities at all; Grade2: had it, and it was bad enough to prevent a significant part of usual activities; Grade3: had it, and it prevented most or all of normal activities, or had to see a doctor for prescription medicine, Redness and swelling: participants measured largest diameter of any injection site reaction and grade them from 0 to 3, where Grade0: measured less than(\<)10 milliliters(mm); Grade1: larger than or equal to(\>=) 10mm and \<20mm; Grade 2: \>=20mm and \<50mm; Grade3: \>=50mm. Participants with multiple symptoms in same category were counted once per category using symptom with maximum grade
Time frame: Within 7 days post vaccination
Number of Participants Reporting Solicited Systemic Reactions
Solicited reaction (reactogenicity event) was an AE that was pre-listed in eCRF, considered to be related to vaccination recorded by the participant by means of a memory aid between the day of vaccination (Day 0) and Day 7 post vaccination. Systemic events included fever, fatigue, shivering, joint pain, muscle pain, headache, and nausea. Fever: \>=100.4 degree Fahrenheit (ºF) to \<101.1ºF; \>=101.2ºF to \<102.2ºF; \>=102.2ºF; Fatigue, shivering, joint pain, muscle pain, headache and nausea: Grade 0: didn't have it at all; Grade 1: noticed it, but it didn't interfere with usual activities at all; Grade 2: had it, and it was bad enough to prevent a significant part of usual activities; and Grade 3: had it, and it prevented most or all of normal activities, or had to see a doctor for prescription medicine. Participants with multiple symptoms in the same category were counted once per category using the symptom with the maximum grade.
Time frame: Within 7 days post vaccination
Number of Participants Reporting Unsolicited Adverse Events
An AE was defined as any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a study vaccine, whether or not considered to be related to the study vaccine. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted (i.e., solicited) in the eCRF in terms of symptom and/or onset post-vaccination, ascertained during follow-up visit or telephone contact up to (and including) the Day 28 contact, whether reported spontaneously by the participant or in response to general questions about current or interim health status.
Time frame: From Day 0 (post-vaccination) through Day 28 post vaccination
Lot Consistency: Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies Following FluBlok Vaccination
GMTs of anti-influenza antibodies were measured using a single radial immunodiffusion (SRID) assay for 3 strains: A/Solomon Islands \[H1N1\], A/Wisconsin \[H3N2\], and B/Malaysia. Titers were expressed in terms of 1/dilution.
Time frame: Day 28 post vaccination
Percentage of Participants With Positive Cell Culture/Culture-Confirmed Influenza Like Illness as Defined by Centers for Disease Control and Prevention (CDC-ILI)
CDC-defined ILI was defined as fever (body temperature \>=100ºF oral accompanied by cough and/or sore throat, on the same day or on consecutive days) due to strains represented in the vaccine.
Time frame: 14 days post vaccination through and up to 6 months
Percentage of Participants With Seroprotection to Influenza Vaccine Antigens After Vaccination With FluBlok
Anti-influenza antibodies were measured using an HAI assay for 3 strains: A/Solomon Islands \[H1N1\], A/Wisconsin \[H3N2\] and B/Malaysia. Seroprotection was defined as a post-vaccination HAI antibody titer of \>=1:40.
Time frame: 28 days post vaccination
Percentage of Participants With Seroconversion to Influenza Vaccine Antigens After Vaccination With FluBlok
Anti-influenza antibodies were measured using an HAI assay for 3 strains: A/Solomon Islands \[H1N1\], A/Wisconsin \[H3N2\] and B/Malaysia. Seroconversion was defined as a post-vaccination titer of \>=1:40 in participants with undetectable baseline antibody (HI titer = \<1:10) or a \>=4-fold rise in antibody in participants with a baseline titer of \>=1:10, with the achievement of post-vaccination titer of at least 1:40.
Time frame: 28 days post vaccination
The study was conducted at 24 active centers in the United States from 15-September-2007 to 28-May-2008.
| Milestone | FluBlok (Lots A, B, C) | Placebo |
|---|---|---|
| Started | 2344 | 2304 |
| Completed | 2049 | 2022 |
| Not completed | 295 | 282 |
| Withdrew: Adverse events (ae) | 3 | 3 |
| Withdrew: Lost to follow-up | 260 | 251 |
| Withdrew: Withdrew consent | 22 | 14 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Other reason-unspecified | 9 | 13 |
Solicited reaction (reactogenicity event) was an adverse event (AE) that was pre-listed in electronic case report form(eCRF), considered to be related to vaccination and recorded by participant by means of memory aid. Injection sites reaction included pain,bruising,redness,swelling. Pain and bruising:Grade0: didn't have it at all; Grade1: noticed it, but it didn't interfere with usual activities at all; Grade2: had it, and it was bad enough to prevent a significant part of usual activities; Grade3: had it, and it prevented most or all of normal activities, or had to see a doctor for prescription medicine, Redness and swelling: participants measured largest diameter of any injection site reaction and grade them from 0 to 3, where Grade0: measured less than(\<)10 milliliters(mm); Grade1: larger than or equal to(\>=) 10mm and \<20mm; Grade 2: \>=20mm and \<50mm; Grade3: \>=50mm. Participants with multiple symptoms in same category were counted once per category using symptom with maximum grade
| Participants | FluBlok (Lots A, B, C) | Placebo |
|---|---|---|
| Injection site pain- Grade 0 | 1421 | 2050 |
| Injection site pain- Grade 1 | 797 | 177 |
| Injection site pain- Grade 2 | 52 | 3 |
| Injection site pain- Grade 3 | 2 | 1 |
| Injection site bruising- Grade 0 | 2197 | 2172 |
| Injection site bruising- Grade 1 | 68 | 57 |
| Injection site bruising- Grade 2 | 6 | 1 |
| Injection site bruising- Grade 3 | 1 | 1 |
| Injection site redness- Grade 0 | 2181 | 2184 |
| Injection site redness- Grade 1 | 72 | 40 |
| Injection site redness- Grade 2 | 15 | 6 |
| Injection site redness- Grade 3 | 4 | 1 |
| Injection site swelling- Grade 0 | 2195 | 2189 |
| Injection site swelling- Grade 1 | 55 | 34 |
| Injection site swelling- Grade 2 | 16 | 6 |
| Injection site swelling- Grade 3 | 6 | 2 |
Solicited reaction (reactogenicity event) was an AE that was pre-listed in eCRF, considered to be related to vaccination recorded by the participant by means of a memory aid between the day of vaccination (Day 0) and Day 7 post vaccination. Systemic events included fever, fatigue, shivering, joint pain, muscle pain, headache, and nausea. Fever: \>=100.4 degree Fahrenheit (ºF) to \<101.1ºF; \>=101.2ºF to \<102.2ºF; \>=102.2ºF; Fatigue, shivering, joint pain, muscle pain, headache and nausea: Grade 0: didn't have it at all; Grade 1: noticed it, but it didn't interfere with usual activities at all; Grade 2: had it, and it was bad enough to prevent a significant part of usual activities; and Grade 3: had it, and it prevented most or all of normal activities, or had to see a doctor for prescription medicine. Participants with multiple symptoms in the same category were counted once per category using the symptom with the maximum grade.
| Participants | FluBlok (Lots A, B, C) | Placebo |
|---|---|---|
| Fever (>=100.4ºF) | 2238 | 2188 |
| Fever (>=100.4 to <101.1ºF) | 8 | 5 |
| Fever (>=101.2 to <102.2ºF) | 5 | 6 |
| Fever (>=102.2ºF) | 4 | 1 |
| Fatigue- Grade 0 | 1932 | 1898 |
| Fatigue- Grade 1 | 250 | 256 |
| Fatigue- Grade 2 | 78 | 66 |
| Fatigue- Grade 3 | 12 | 11 |
| Shivering- Grade 0 | 2202 | 2160 |
| Shivering- Grade 1 | 52 | 54 |
| Shivering- Grade 2 | 12 | 13 |
| Shivering- Grade 3 | 6 | 4 |
| Joint pain- Grade 0 | 2183 | 2148 |
| Joint pain- Grade 1 | 69 | 67 |
| Joint pain- Grade 2 | 14 | 12 |
| Joint pain- Grade 3 | 6 | 4 |
| Muscle pain- Grade 0 | 2033 | 2077 |
| Muscle pain- Grade 1 | 197 | 124 |
| Muscle pain- Grade 2 | 36 | 22 |
| Muscle pain- Grade 3 | 6 | 8 |
| Headache- Grade 0 | 1923 | 1877 |
| Headache- Grade 1 | 264 | 273 |
| Headache- Grade 2 | 70 | 68 |
| Headache- Grade 3 | 15 | 13 |
| Nausea- Grade 0 | 2143 | 2122 |
| Nausea- Grade 1 | 94 | 74 |
| Nausea- Grade 2 | 29 | 25 |
| Nausea- Grade 3 | 6 | 10 |
An AE was defined as any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a study vaccine, whether or not considered to be related to the study vaccine. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted (i.e., solicited) in the eCRF in terms of symptom and/or onset post-vaccination, ascertained during follow-up visit or telephone contact up to (and including) the Day 28 contact, whether reported spontaneously by the participant or in response to general questions about current or interim health status.
| Participants | FluBlok (Lots A, B, C) | Placebo |
|---|---|---|
| Number of Participants Reporting Unsolicited Adverse Events | 61 | 67 |
GMTs of anti-influenza antibodies were measured using a single radial immunodiffusion (SRID) assay for 3 strains: A/Solomon Islands \[H1N1\], A/Wisconsin \[H3N2\], and B/Malaysia. Titers were expressed in terms of 1/dilution.
| Titer (1/dilution) | FluBlok: Lot A | FluBlok: Lot B | FluBlok: Lot C |
|---|---|---|---|
| A/Solomon Islands (H1N1) | 346.15 (291.96 to 410.41) | 322.95 (274.80 to 379.55) | 381.00 (321.79 to 451.10) |
| A/Wisconsin (H3N2) | 390.34 (324.83 to 469.06) | 192.25 (159.59 to 231.59) | 240.01 (200.14 to 287.82) |
| B/Malaysia | 182.10 (151.95 to 218.24) | 205.95 (174.16 to 243.55) | 215.34 (179.31 to 258.62) |
CDC-defined ILI was defined as fever (body temperature \>=100ºF oral accompanied by cough and/or sore throat, on the same day or on consecutive days) due to strains represented in the vaccine.
| percentage of participants | FluBlok (Lots A, B, C) | Placebo |
|---|---|---|
| Percentage of Participants With Positive Cell Culture/Culture-Confirmed Influenza Like Illness as Defined by Centers for Disease Control and Prevention (CDC-ILI) | 0.04 | 0.2 |
Anti-influenza antibodies were measured using an HAI assay for 3 strains: A/Solomon Islands \[H1N1\], A/Wisconsin \[H3N2\] and B/Malaysia. Seroprotection was defined as a post-vaccination HAI antibody titer of \>=1:40.
| percentage of participants | FluBlok (Lots A, B, C) |
|---|---|
| A/Solomon Islands (H1N1) | 99 (97.1 to 99.5) |
| A/Wisconsin (H3N2) | 97 (94.8 to 98.3) |
| B/Malaysia | 96 (94.0 to 97.8) |
Anti-influenza antibodies were measured using an HAI assay for 3 strains: A/Solomon Islands \[H1N1\], A/Wisconsin \[H3N2\] and B/Malaysia. Seroconversion was defined as a post-vaccination titer of \>=1:40 in participants with undetectable baseline antibody (HI titer = \<1:10) or a \>=4-fold rise in antibody in participants with a baseline titer of \>=1:10, with the achievement of post-vaccination titer of at least 1:40.
| percentage of participants | FluBlok (Lots A, B, C) |
|---|---|
| A/Solomon Islands (H1N1) | 78 (73.5 to 81.5) |
| A/Wisconsin (H3N2) | 81 (77.1 to 84.6) |
| B/Malaysia | 52 (47.0 to 56.5) |
Collected over Unsolicited non-serious AEs: Day 0 to Day 28 post vaccination, Solicited reactions: within 7 days post vaccination, SAE: through the end of influenza season (up to 6 months). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FluBlok (Lots A, B, C) | 1/2,344 (0%) | 30/2,344 (1.3%) | 152/2,344 (6.5%) |
| Placebo | 1/2,304 (0%) | 34/2,304 (1.5%) | 120/2,304 (5.2%) |
| Event | FluBlok (Lots A, B, C) | Placebo |
|---|---|---|
| DepressionPsychiatric disorders | 0/2344 | 3/2304 |
| AppendicitisInfections and infestations | 1/2344 | 2/2304 |
| Kidney infectionInfections and infestations | 0/2344 | 2/2304 |
| DehydrationMetabolism and nutrition disorders | 0/2344 | 2/2304 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/2344 | 2/2304 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/2344 | 0/2304 |
| Suicide attemptPsychiatric disorders | 2/2344 | 1/2304 |
| LymphadenopathyBlood and lymphatic system disorders | 0/2344 | 1/2304 |
| Myocardial infarctionCardiac disorders | 0/2344 | 1/2304 |
| Supraventricular tachycardiaCardiac disorders | 0/2344 | 1/2304 |
| Event | FluBlok (Lots A, B, C) | Placebo |
|---|---|---|
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 42/2344 | 49/2304 |
| CoughRespiratory, thoracic and mediastinal disorders | 48/2344 | 37/2304 |
| HeadacheNervous system disorders | 35/2344 | 42/2304 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 37/2344 | 31/2304 |
Analysis performed on safety population that included participants who received study vaccine, according to the treatment (FluBlok or Placebo) actually received.
| Age, Categorical(Participants) | FluBlok (Lots A, B, C) | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 2344 | 2304 | 4648 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | FluBlok (Lots A, B, C) | Placebo | Total |
|---|---|---|---|
| Female | 1391 | 1349 | 2740 |
| Male | 953 | 955 | 1908 |
| Race/Ethnicity, Customized(Participants) | FluBlok (Lots A, B, C) | Placebo | Total |
|---|---|---|---|
| Race/Ethnicity — White/Caucasian | 1570 | 1530 | 3100 |
| Race/Ethnicity — Black/African-American | 430 | 447 | 877 |
| Race/Ethnicity — Latino/Hispanic | 250 | 239 | 489 |
| Race/Ethnicity — Asian | 62 | 52 | 114 |
| Race/Ethnicity — American Indian/Alaska Native | 7 | 9 | 16 |
| Race/Ethnicity — Native Hawaiian/Pacific Islander | 6 | 8 | 14 |
| Race/Ethnicity — Other-unspecified | 19 | 19 | 38 |
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Sep 2007 to primary completion in May 2008, 8 months.
Results were first posted in Feb 2021, 12 years 8 months after primary completion. A results delay was requested in Apr 2011.
Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 8 months is close to that.
Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: FluBlok